{"Symbol": "AKBA", "AssetType": "Common Stock", "Name": "Akebia Ther", "Description": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.", "CIK": "1517022", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "DRUG MANUFACTURERS - SPECIALTY & GENERIC", "Address": "245 FIRST STREET, CAMBRIDGE, MA, UNITED STATES, 02142", "OfficialSite": "https://www.akebia.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "321093000", "EBITDA": "32246000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.157", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.08", "RevenuePerShareTTM": "0.917", "ProfitMargin": "-0.0707", "OperatingMarginTTM": "0.0757", "ReturnOnAssetsTTM": "0.048", "ReturnOnEquityTTM": "-5.53", "RevenueTTM": "225071000", "GrossProfitTTM": "187526000", "DilutedEPSTTM": "-0.08", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.57", "AnalystTargetPrice": "4.6", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "4", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "10.08", "PriceToSalesRatioTTM": "1.427", "PriceToBookRatio": "7.72", "EVToRevenue": "0.921", "EVToEBITDA": "9.76", "Beta": "0.373", "52WeekHigh": "4.079", "52WeekLow": "1.2", "50DayMovingAverage": "1.505", "200DayMovingAverage": "2.603", "SharesOutstanding": "265366000", "SharesFloat": "259109000", "PercentInsiders": "4.235", "PercentInstitutions": "48.807", "DividendDate": "None", "ExDividendDate": "None"}